You are here

Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis

Last updated on February 22, 2019

FOR MORE INFORMATION
Study Location
Tucson Veterans Administration Med Ctr
Tucson, Arizona, 85724 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Meningitis, HIV Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
13 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Concurrent Medication:

Allowed:

- Immunosuppressive therapy including corticosteroids and/or cytotoxic agents.

- Antiviral therapy (e.g., zidovudine (AZT)).

- Prophylaxis for Pneumocystis carinii pneumonia (PCP).

- Any exceptions to use of concomitant medications must be approved by Pfizer Central
Research prior to study entry.

Concurrent Treatment:

Allowed:

- Radiation therapy for mucocutaneous Kaposi's sarcoma.

Patients must:

- Be clinically judged to be in need of treatment for coccidioidal meningitis.

- Have > 1 week life expectancy.

- Allowed:

- Immunocompromised patients.

- Patients with renal disease will have the dose of fluconazole adjusted and serum
levels may be monitored.

Prior Medication:

Allowed:

- Amphotericin B.

- Ketoconazole.

- Miconazole.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

- Current antifungal infection that is responding to another agent. Findings of
improvement include one of the following, while on other therapy (without subsequent
relapse of the item):

- CSF culture conversion from positive to negative.

- OR

- CSF antibody titer decrease of at least one dilution.

- OR

- Improvement in signs and symptoms of meningitis.

- Have received more than minimal systemic antifungal therapy (see Patient Inclusion
Criteria), unless they meet criteria for previous treatment failure or relapse. They
must not have received this therapy since the time relapse or failure was documented,
except for minimal antifungal therapy allowed in Patient Inclusion Criteria.

- Immediately life-threatening coccidioidomycosis defined as infection of such a degree
of clinical severity that the patient would be expected to die within 1 week, if
untreated, based on clinical judgment.

- Experienced a prior allergic reaction or major side effect from an imidazole or
triazole compound.

Concurrent Medication:

Excluded:

- Barbiturates.

- Phenytoin.

- Oral hypoglycemics.

- Coumadin type anticoagulants.

- Other systemic or intrathecal antifungal therapy.

- Other experimental agents with exceptions noted in concomitant medications section.

- Any exceptions to these prohibitions of concomitant medications must be approved by
Pfizer Central Research prior to study entry.

Patients with the following are excluded:

- Are responding or are improving on current antifungal therapy with another agent.

- Have received more than minimal systemic antifungal therapy (see Patient Inclusion
Criteria), unless they meet criteria for previous treatment failure or relapse. They
must not have received this therapy since the time relapse or failure was documented,
except for minimal antifungal therapy allowed in Patient Inclusion Criteria.

- Immediately life-threatening coccidioidomycosis defined as infection of such a degree
of clinical severity that the patient would be expected to die within 1 week, if
untreated, based on clinical judgment.

- Experienced a prior allergic reaction or major side effect from an imidazole or
triazole compound.

NCT00002010
Pfizer
Completed
Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now